Dihydroethanoanthracene Derivatives as In Vitro Malarial Chloroquine Resistance Reversal Agents

Julie Millet,1,2 Marylin Torrentino-Madamet,1,2 Sandrine Alibert,2,3 Christophe Rogier,1,2 Christiane Santelli-Rouvier,2,3 Joel Mosnier,1,2 Eric Baret,1,2 Jacques Barbe,2,3 Daniel Parzy,1,2 and Bruno Pradines1,2*

Unité de Parasitologie, Institut de Médecine Tropicale du Service de Santé des Armées,1 GERCTOP-UMR CNRS 6009, Faculté de Pharmacie,2 and Institut Féde´ratif de la Recherche 48,3 Marseille, France

Received 15 December 2003/Returned for modification 28 January 2004/Accepted 10 March 2004

The ability of four 9,10-dihydroethanoanthracene derivatives (BG920, BG932, BG958, and BG996), as well as verapamil and promethazine, to reverse chloroquine resistance was assessed against 24 chloroquine-resistant and 10 chloroquine-susceptible strains of Plasmodium falciparum from different countries. The 9,10-dihydroethanoanthracene derivatives clearly increase chloroquine susceptibility only in chloroquine-resistant isolates.

Isolates of P. falciparum. Thirty-four strains of Plasmodium falciparum, 27 isolates and 7 clones from several countries, were used for this study. Twenty-five isolates were African strains originating from nine countries, including Cameroon (two strains), Comoros (seven strains), Ivory Coast (four strains), Djibouti (two strains), Gabon (one strain), Gambia (one strain), Niger (two strains), Uganda (one strain), and an undetermined African country (one strain). Six isolates came from three Asian countries, including Cambodia (four strains), Indochina (one strain), and Thailand (one strain). Additionally, one strain came from Brazil, and another was a Caribbean strain. Among the 34 parasites, 24 were CQR and 10 were CQ susceptible (CQS). All parasites were maintained in culture in RPMI 1640 medium (Invitrogen, Paisley, United Kingdom) supplemented with 10% human serum and buffered with 25 mM HEPES and 25 mM NaCO3 (hematocrit, 1.5%; parasitemia, 0.5%).

* Corresponding author. Mailing address: IMTSSA, Unité de Parasitologie, Bd Charles Livon, Parc le Pharo, BP 46, 13998 Marseille Armées, France. Phone: 33 4 91 15 01 10. Fax: 33 4 91 15 01 64. E-mail: bruno.pradines@free.fr.
Drugs. The synthesis of BG920, BG932, BG958, and BG996 was described previously (2, 3, 14). CQ, VER, and PRM were obtained from Sigma Chemical (St. Louis, Mo.). CQ was diluted in sterile distilled water. DEA derivatives, VER, and PRM were diluted in methanol. Final concentrations of CQ distributed for the evaluation of drug interaction ranged from 25 to 3,210 nM for resistant strains and from 3 to 200 nM for susceptible strains. VER, PRM, and DEAs were used at the following concentrations, corresponding to 1/5 and 1/20, respectively, of their intrinsic IC50s against the CQR clone W2: 2,600 and 650 nM for VER, 3,700 and 925 nM for PRM, 860 and 215 nM for BG920, 420 and 105 nM for BG932, 2,350 and 585 nM for BG958, and 1,600 and 400 nM for BG996. At these concentrations, none of the molecules has detectable antiplasmodial activity.

In vitro assay. For in vitro isotopic microtests to assess synergy between CQ and DEA compounds, 25 μl of CQ, 25 μl of the drug tested, and 200 μl of the suspension of parasitized red blood cells (final parasitemia, 0.5%; final hematocrit, 1.5%) were distributed in 96-well plates. Parasite growth was assessed by adding 1 μCi of [3H]hypoxanthine with a specific activity of 14.1 Ci/mmol (Amersham, Buckinghamshire, United Kingdom) to each well at time zero. The plates were then incubated for 48 h at 37°C in an atmosphere of 10% O2, 5% CO2, and 85% N2, with a humidity of 95%. Immediately after incubation, the plates were frozen and then thawed to lyse...
erythrocytes. The contents of each well were collected on standard filter microplates (Unifilter GF/B; Perkin-Elmer, Courtaboeuf, France) and washed by using a cell harvester (FilterMate Cell Harvester; Perkin-Elmer). Filter microplates were dried, and 25 μl of scintillation cocktail (Microscint O; Perkin-Elmer) was placed in each well. Radioactivity incorporated by the parasites was measured with a scintillation counter (Top Count; Perkin-Elmer).

The IC_{50}, i.e., the drug concentration corresponding to 50% of the uptake of [3H]hypoxanthine by the parasite in drug-free control wells, was determined by nonlinear regression analysis of log dose-response curves. Data were analyzed after logarithmic transformation and expressed as the geometric mean IC_{50}.

**Evaluation of drug effect.** To evaluate the capacities of the four DEAs, VER, and PRM to potentiating CQ activity against isolates of *P. falciparum*, an activity enhancement index of CQ was defined as the difference between the IC_{50} measured with CQ alone and the IC_{50} measured for CQ associated with molecules of potentiation divided by the IC_{50} measured for CQ alone.

**Results.** The CQ IC_{50} ranged between 156 and 858 nM for isolates resistant to CQ and between 17 and 65 nM for parasites susceptible to CQ (Fig. 2).

The CQ IC_{50} against CQS isolates and clones were not significantly modified by combination with DEAs, VER, or PRM (Fig. 2). CQ IC_{50} against CQR isolates and clones were significantly reduced when combined with DEAs, VER, or PRM (*P < 0.001*). The CQ IC_{50} estimated in the presence of CQ were significantly higher than the CQ IC_{50} estimated in the presence of CQ associated with molecules of potentiation (*P < 0.001*).

The activity enhancement index of CQ by each molecule of potentiation at the studied concentration was significantly higher for CQR isolates compared to CQS parasites (*P < 0.0001*). Potentiation of CQ activity on CQR parasites is dose dependent (*P < 0.001*) (Fig. 2).

The activity enhancement index of CQ in the presence of BG958 was significantly higher than the indices measured in the presence of the other DEAs (*P < 0.0005*). The increase of CQ activity in the presence of BG958 was equivalent to that observed in the presence of PRM for CQR isolates. BG958 at 585 and 2,350 nM reversed in vitro the CQ resistance, i.e., decreased CQ IC_{50} below the threshold of 100 nM, in 42% (10 out of 24) and 92% (22 out of 24) of CQR isolates, respectively (Table 1).

**Discussion.** Quinoline resistance in *P. falciparum* is frequently compared to multidrug resistance in mammalian cells, in part because of the observations that CQ resistance could be reversed by P-glycoprotein substrates such as VER and PRM. Our results suggest that the mechanism of action of the DEAs is associated with resistance properties; the DEA reversal of resistance in *P. falciparum* is specific for resistant parasites. DEAs clearly increase CQ susceptibility in CQR isolates, although not to the levels of the naturally susceptible strains; this result has been reported with very few isolates (one to three isolates) for VER (9), desipramine (7, 12), and PRM (19). These DEAs fully or partially reversed resistance in all CQR isolates from all different geographic regions (Africa, Asia, and South America).

CQ resistance can be either fully or partially sensitive to the presence of VER, and recent reports suggest that this behavior may be associated with the presence of specific sequences in the *pfcrt* gene, which encodes a vacuolar transport protein (13). While genetic differences in CQ resistance are known (13, 18, 28), the reverse phenotypic response may exist in all geographic regions, independent of the allelic variations. However, it has been reported that VER reversibility was more pronounced in clones expressing recombinant *pfcrt* or strains from the Old World carrying the *pfcrt* CVIET haplotype than in parasite isolates or clones expressing the recombinant New World allele carrying the SVMNT haplotype (18, 25). It would be interest to know if these *pfcrt* polymorphisms were related to or were independent of the DEA CQ sensitization potential.

BG958 fully or partially reversed resistance in all CQR strains. The observation reported here suggests that BG958 is a good candidate for further studies. Evaluation of its in vivo reversal of CQ resistance and association with *pfcrt* and *pfdmrl* polymorphisms is ongoing. Furthermore, the use of BG958 in combination with CQ, due to the low cost of BG958 synthesis, may be an economically viable proposition for developing countries and may be a more effective strategy than the introduction of another antimalarial drug at the national level.

This work is supported by the Délégation Générale pour l’Armement (DGA funder no. 010808/03-5). This work was carried out as a part of the COST B16 European Program.

**REFERENCES**


